Hao Yan, Yang Yulin, Wang Yongchao, Li Jian
Department of Cardiology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Curr Med Res Opin. 2022 Oct;38(10):1663-1672. doi: 10.1080/03007995.2022.2078080. Epub 2022 May 26.
As a residual risk factor for coronary heart disease, lipoprotein(a) [Lp(a)] is associated with the occurrence of cardiovascular events after percutaneous coronary intervention (PCI). The revascularization rate after PCI is high among diabetic patients. However, the relationship between Lp(a) and revascularization after PCI in type 2 diabetes mellitus (T2DM) patients with acute coronary syndrome (ACS) remains unclear.
The investigation was a single-center, observational, retrospective cohort study. Patients with T2DM who were first diagnosed with ACS and underwent PCI were included in the study. As a result, 362 patients were enrolled and divided into three groups according to tertiles on basis of Lp(a) levels (11.48 mg/dL and 21.70 mg/dL). The incidence of major adverse cardiac events (MACEs), including cardiac death, revascularization due to myocardial ischemia, readmission due to angina, and nonfatal stroke, was evaluated. Subgroups were established according to the low-density lipoprotein cholesterol (LDL-C) level (70 mg/dL).
During follow-up (median: 2.0 years), 69 MACEs occurred, and 76.81% of these patients underwent revascularization. The Lp(a) level in the MACE group was significantly higher than that in the non-MACE group (22.90 mg/dL vs. 14.10 mg/dL, < .001). Kaplan-Meier analysis revealed that the incidence of adverse cardiovascular events was significantly higher in the high Lp(a) groups than in the low Lp(a) groups ( = .001), mainly because of the increased occurrence of revascularization irrespective of LDL-C level (<70 mg/dL; ≥70 mg/dL, both < .05) rather than death, nonfatal stroke, or hospital readmission due to angina (both > .05). The receiver operating characteristic (ROC) curve showed that the area under the curve (AUC) for Lp(a) in predicting the occurrence of MACE and revascularization were 0.664 and 0.668 respectively, both < .05. Furthermore, multivariate Cox regression models indicated that Lp(a) was independently associated with revascularization [medium Lp(a) category: HR (95% CI): 2.988 (1.164-7.671), = .023; high Lp(a) category: HR (95% CI): 4.937 (2.023-12.052), < .001].
Lp(a) was an independent predictor of revascularization in patients with ACS complicated with T2DM, regardless of LDL-C levels. This suggests that Lp(a) measurement may help identify high-risk diabetic patients with ACS.
作为冠心病的残余风险因素,脂蛋白(a)[Lp(a)]与经皮冠状动脉介入治疗(PCI)后心血管事件的发生相关。糖尿病患者PCI后的血管再通率较高。然而,急性冠状动脉综合征(ACS)合并2型糖尿病(T2DM)患者中,Lp(a)与PCI后血管再通之间的关系仍不明确。
本研究为单中心、观察性、回顾性队列研究。纳入首次诊断为ACS并接受PCI的T2DM患者。最终,362例患者入组,并根据Lp(a)水平三分位数分为三组(11.48mg/dL和21.70mg/dL)。评估主要不良心脏事件(MACE)的发生率,包括心源性死亡、因心肌缺血导致的血管再通、因心绞痛再次入院以及非致死性卒中。根据低密度脂蛋白胆固醇(LDL-C)水平(70mg/dL)建立亚组。
随访期间(中位时间:2.0年),发生69例MACE,其中76.81%的患者接受了血管再通治疗。MACE组的Lp(a)水平显著高于非MACE组(22.90mg/dL vs. 14.10mg/dL,P<0.001)。Kaplan-Meier分析显示,高Lp(a)组不良心血管事件的发生率显著高于低Lp(a)组(P=0.001),主要原因是无论LDL-C水平如何(<70mg/dL;≥70mg/dL,均P<0.05),血管再通的发生率增加,而非死亡、非致死性卒中和因心绞痛再次入院的发生率增加(均P>0.05)。受试者工作特征(ROC)曲线显示,Lp(a)预测MACE和血管再通发生的曲线下面积(AUC)分别为0.664和0.668,均P<0.05。此外,多因素Cox回归模型表明,Lp(a)与血管再通独立相关[中等Lp(a)类别:HR(95%CI):2.988(1.164 - 7.671),P=0.023;高Lp(a)类别:HR(95%CI):4.937(2.023 - 12.052),P<0.001]。
Lp(a)是ACS合并T2DM患者血管再通的独立预测因素,与LDL-C水平无关。这表明检测Lp(a)可能有助于识别高危的ACS糖尿病患者。